Partnership Objective
To license Trinity-developed fertility and diagnostic innovations, enabling the commercial development of novel reproductive health products.
Trinity Added Value
- Patented IP developed through two Enterprise Ireland Innovation Partnership projects.
- Scientific expertise from Trinity’s School of Biochemistry and Immunology.
- Active support from the TTO in IP protection, licensing, and ongoing patent management.
Partnership Activities and Approach
- Exclusive licences for a fertility gel and a sperm health biomarker diagnostic.
- Product development plans spanning formulation, validation, and regulatory submission.
- Ongoing collaboration discussions beyond the licensed technologies.
Impact
Enabled Kora Healthcare to expand into the male infertility market, with new products targeting a combined global market of over €23 billion by 2025.